In acute myeloid leukemia, a preclinical study found a promising and potent anti-leukemic strategy involving the co-administration of midostaurin (a TKI that inhibits the FLT3 pathway) and a novel FLT3-targeting ADC [112]. The gene discussed is FLT3; the disease is acute myeloid leukemia.